ViCentra, a Dutch medical device company that commercializes the Kaleido insulin patch pump system, has raised an additional $13 million as part of its Series D financing to expand manufacturing, strengthen commercial operations, and accelerate preparations for bringing its next-generation Kaleido system to the U.S. market.
ViCentra Secures an Additional $13M to Accelerate Growth and Advance Next-Gen Insulin System
January 8, 2026